REGENXBIO, Inc. RGNX 深 滬
等待開盤 01-28 09:30:00 美东时间
13.41
-0.445
-3.21%
華盛通- 最 高14.17
- 今 開13.91
- 成交量 69.79万股
- 最 低 13.2582
- 昨 收 13.855
- 總市值 6.79亿
- 52周最高 16.19
- 市盈率 靜 --
- 換手率 1.38%
- 52周最低 5.035
- 委 比 92.44%
- 總股本 5062.31万
- 歷史最高 85.10
- 量 比 0.71
- 振 幅 6.58%
- 歷史最低 5.035
- 每 手 1
- 風險率 2.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Reported Sunday, REGENXBIO Highlights 2026 Catalysts As RGX-202 Shows Durable 18-Month Functional Benefit, With FDA PDUFA, BLA Filing, And Multiple Pivotal Readouts Expected
New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months Robust patient enrollment in confirmatory trial continues, expect majority of patients to be dosed
01-12 16:17
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers SciSparc (NASDAQ:SPRC) shares rose 6.3% to $1.46 during Monday's after...
2025-12-30 05:05
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Leerink Partners Maintains Outperform on Regenxbio, Raises Price Target to $20
Leerink Partners analyst Mani Foroohar maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $16 to $20.
2025-12-16 04:50
Regenxbio files $300M mixed shelf offering
Regenxbio (RGNX) has filed a shelf registration to offer up to $300M in securities. The offering may include common stock, preferred stock, debt securities, warrants, rights, or units, in one or more ...
2025-11-27 06:34
REGENXBIO to Participate in Upcoming Investor Conference
ROCKVILLE, Md., Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Con...
2025-11-25 20:05
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.
2025-11-20 20:30
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
